Investigators who designed a base-editing treatment are planning an "umbrella of umbrellas" trial, while others are developing roadmaps to guide personalized treatments.

People who had a daily cup of coffee had a lower risk of new episodes of atrial fibrillation compared with people who ...

N EW ORLEANS -- The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

The Canadian Cancer Society (CCS) and the Quebec - Clinical Research Organization in Cancer (Q-CROC) are pleased to launch Cancer Trials Canada, the country's only national, bilingual, patient-centric ...

At 12 weeks, a combination pill containing candesartan cilexetil, amlodipine, and chlorthalidone improved BP in patients with hypertension.

Yet another study by Harald Walach et al on the placebo effect has been retracted. The objective of the paper was to determine what contributes to the size of the placebo effect in clinical drug ...

Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for ...

Authors write that a recent evaluation of home visiting programs should give pause to the concept’s champions in Congress ...

The world celebrates science today. The United Nations proclaimed November 10th World Science Day for Peace and Development ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...